An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Marta CompteSeandean L HarwoodAinhoa Erce-LlamazaresAntonio Tapia-GalisteoEduardo RomeroIrene FerrerEva Maria Garrido-MartinAna B EnguitaMaría Carmen OchoaBelén BlancoMarta OteoNekane MerinoDaniel Nehme-ÁlvarezOana HangiuCarmen Domínguez-AlonsoManuela ZoncaAngel Ramírez-FernándezFrancisco J BlancoMiguel Ángel Morcillo AlonsoInes G MuñozIgnacio MeleroJosé L Rodriguez-PeraltoLuis Paz-AresLaura SanzLuis Alvarez-VallinaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These results demonstrate the nontoxic broad antitumor activity of humanized Fc-free tumor-specific 4-1BB-agonistic trimerbodies and their synergy with checkpoint blockers, which may provide a way to elicit responses in most patients with cancer while avoiding Fc-mediated adverse reactions.